AbbVie cuts Q3 and full-year 2026 adjusted EPS guidance after IPR&D charge

AbbVie's revised Q3 2026 outlook

On October 5, 2026, AbbVie said its third-quarter results would include a pre-tax charge of $216 million tied to acquired in-process research and development and milestone payments, reducing both GAAP and adjusted diluted EPS by $0.11. The drugmaker set Q3 adjusted EPS guidance of $3.73 to $3.77, below the analyst consensus of $3.84 to $3.85 compiled by data providers. The quarterly update followed a broader reassessment of the company's full-year earnings outlook.

Full-year 2026 adjusted EPS guidance also lowered

AbbVie cut its full-year 2026 adjusted diluted EPS guidance to a range of $13.76 to $13.96, down from its prior $13.87 to $14.07 range and below the consensus of approximately $14.01 to $14.02. The company attributed the reduction in part to the $216 million IPR&D and milestone charge taken in the third quarter. IPR&D charges typically stem from acquisitions of early-stage drug candidates or technologies that have not yet reached regulatory approval, and AbbVie noted that the expense would weigh on reported earnings while not affecting adjusted earnings excluding such one-time costs.

Share price reaction and analyst stance

Shares of AbbVie opened at $265.93 and were trading near a 12-month high, up roughly 1.2% on the day of the update. According to MarketBeat data, the stock carries a consensus "Moderate Buy" rating, with two analysts assigning a Strong Buy, twenty-two a Buy and six a Hold, and an average price target of $272.39. Recent analyst moves cited in the coverage include HSBC raising its target from $300 to $315, Canaccord Genuity Group lifting its target from $282 to $290, Oppenheimer increasing its target from $244 to $258, Royal Bank Of Canada moving from $260 to $280, and Barclays raising its objective from $275 to $300.

Dividend and capital return context

AbbVie declared a quarterly cash dividend of $1.73 per share, equivalent to $6.92 annualized and a roughly 2.55% to 2.6% yield, with the dividend payable November 16 to shareholders of record October 15. The company has grown its dividend at a 5.2% annualized rate over the past three years, though its payout ratio sits at about 85%, a level cited by analysts as a watch item for sustainability. AbbVie's market capitalization was reported at $469.63 billion, and GuruFocus estimated GF Value at $221.64 per share against a then-current price near $265.76, suggesting modest overvaluation on the GuruFocus model.

Portfolio context and pipeline exposure

AbbVie is a global biopharmaceutical company with leadership positions in immunology, oncology, neuroscience and aesthetics, anchored by blockbusters Skyrizi, Rinvoq and Botox. The IPR&D charge signals continued reinvestment in early-stage drug candidates or technologies through acquisitions or milestone arrangements, a recurring feature of AbbVie's pipeline strategy. Insider activity over the prior twelve months showed net selling, with no insider purchases and about $17.7 million of shares sold, while eighteen premium tracked investors held ABBV with an even split between adding and trimming positions.